MENLO PARK, CA--(Marketwired - April 30, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 37151424.
A replay will be available through May 21, 2014 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 37151424.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Korlym® (mifepristone) 300 mg Tablets, a first generation GR antagonist, is the company's first FDA-approved medication for use in the treatment of patients with Cushing's syndrome. Corcept has a phase 3 trial underway for mifepristone for treatment of psychotic depression and a phase 1 trial for mifepristone in combination with chemotherapy for the treatment of relapsed, metastatic triple-negative breast cancer. It also has a portfolio of selective GR antagonists that block the effects of cortisol without blocking the effects of progesterone. The company owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of disorders. It also holds composition of matter patents for its selective GR antagonists. For more information about Corcept please visit: www.corcept.com.